Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PNA-mediated Inhibition of the SENP1 Molecular Hub as a Potential Therapeutic Approach for the Suppression of Osteosarcoma Growth and Metastasis (PNA-OS)

NCT03798587 is registered in ClinicalTrials.gov with I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio as lead sponsor.

NCT NCT03798587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03798587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PNA-mediated Inhibition of the SENP1 Molecular Hub as a Potential Therapeutic Approach for the Suppression of Osteosarcoma Growth and Metastasis (PNA-OS)
Lead sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2020
Completion date
December 31, 2021
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary osteosarcoma of bone